Agreement Levels Between OSEMPET1/OSEMPET2 Scenario and Other Scenarios Involving Reconstruction Inconsistency
| κ (95% confidence interval) | ||||
| Scenario | Overall (n = 86) | NSCLC (n = 51) | Colorectal liver metastases (n = 24) | Melanoma metastases (n = 11) |
| OSEMPET1/OSEMPET2 vs. OSEMPET1/PSF ± TOF.EQPET2 | 0.95 (0.90–1.00) | 0.94 (0.87–1.00) | 1.00 (1.00–1.00) | 0.85 (0.59–1.00) |
| OSEMPET1/OSEMPET2 vs. PSF ± TOF.EQPET1/OSEMPET2 | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) |
| OSEMPET1/OSEMPET2 vs. OSEMPET1/PSF ± TOFPET2 | 0.72 (0.60–0.84) | 0.74 (0.60–0.90) | 0.71 (0.48–0.94) | 0.58 (0.18–0.99) |
| OSEMPET1/OSEMPET2 vs. PSF ± TOFPET1/OSEMPET2 | 0.79 (0.69–0.90) | 0.75 (0.60–0.90) | 0.76 (0.55–0.97) | 1.00 (1.00–1.00) |
| OSEMPET1/OSEMPET2 vs. PSF ± TOF.EQPET1/PSF ± TOF.EQPET2 | 0.93 (0.87–1.00) | 0.91 (0.83–1.00) | 1.00 (1.00–1.00) | 0.86 (0.59–1.00) |
| OSEMPET1/OSEMPET2 vs. PSF ± TOFPET1/PSF ± TOFPET2 | 0.92 (0.85–0.99) | 0.92 (0.83–1.00) | 0.94 (1.83–1.00) | 0.86 (0.59–1.00) |
NSCLC = non–small cell lung cancer.
Data in parentheses are 95% confidence intervals.